SMS Pharmaceuticals（SMSPHARMA）株式概要エス・エム・エス・ファーマシューティカルズ・リミテッドは、医薬品原薬（API）とその中間体をインド国内外で製造・販売している。 詳細SMSPHARMA ファンダメンタル分析スノーフレーク・スコア評価1/6将来の成長0/6過去の実績5/6財務の健全性4/6配当金0/6報酬過去1年間で収益は47.5%増加しました リスク分析負債は営業キャッシュフローで十分にカバーされていない すべてのリスクチェックを見るSMSPHARMA Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value₹Current Price₹376.5536.5% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-71m15b2016201920222025202620282031Revenue ₹15.4bEarnings ₹1.8bAdvancedSet Fair ValueView all narrativesSMS Pharmaceuticals Limited 競合他社Unichem LaboratoriesSymbol: BSE:506690Market cap: ₹30.4bGufic BiosciencesSymbol: BSE:509079Market cap: ₹36.1bRPG Life SciencesSymbol: NSEI:RPGLIFEMarket cap: ₹37.6bNovartis IndiaSymbol: BSE:500672Market cap: ₹35.5b価格と性能株価の高値、安値、推移の概要SMS Pharmaceuticals過去の株価現在の株価₹376.5552週高値₹447.8052週安値₹207.99ベータ0.321ヶ月の変化1.98%3ヶ月変化0.45%1年変化50.20%3年間の変化309.29%5年間の変化109.95%IPOからの変化948.16%最新ニュース分析記事 • May 31SMS Pharmaceuticals' (NSE:SMSPHARMA) Earnings Are Of Questionable QualityInvestors were disappointed with SMS Pharmaceuticals Limited's ( NSE:SMSPHARMA ) earnings, despite the strong profit...分析記事 • May 28With EPS Growth And More, SMS Pharmaceuticals (NSE:SMSPHARMA) Makes An Interesting CaseIt's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...New Risk • May 23New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 16% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. This is currently the only risk that has been identified for the company.Reported Earnings • May 23Full year 2026 earnings released: EPS: ₹11.15 (vs ₹7.80 in FY 2025)Full year 2026 results: EPS: ₹11.15 (up from ₹7.80 in FY 2025). Revenue: ₹8.95b (up 14% from FY 2025). Net income: ₹1.02b (up 48% from FY 2025). Profit margin: 11% (up from 8.8% in FY 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has increased by 65% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • May 16SMS Pharmaceuticals Limited to Report Q4, 2026 Results on May 22, 2026SMS Pharmaceuticals Limited announced that they will report Q4, 2026 results on May 22, 2026Valuation Update With 7 Day Price Move • Feb 17Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹368, the stock trades at a trailing P/E ratio of 38.4x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 423% over the past three years.最新情報をもっと見るRecent updates分析記事 • May 31SMS Pharmaceuticals' (NSE:SMSPHARMA) Earnings Are Of Questionable QualityInvestors were disappointed with SMS Pharmaceuticals Limited's ( NSE:SMSPHARMA ) earnings, despite the strong profit...分析記事 • May 28With EPS Growth And More, SMS Pharmaceuticals (NSE:SMSPHARMA) Makes An Interesting CaseIt's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...New Risk • May 23New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 16% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. This is currently the only risk that has been identified for the company.Reported Earnings • May 23Full year 2026 earnings released: EPS: ₹11.15 (vs ₹7.80 in FY 2025)Full year 2026 results: EPS: ₹11.15 (up from ₹7.80 in FY 2025). Revenue: ₹8.95b (up 14% from FY 2025). Net income: ₹1.02b (up 48% from FY 2025). Profit margin: 11% (up from 8.8% in FY 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has increased by 65% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • May 16SMS Pharmaceuticals Limited to Report Q4, 2026 Results on May 22, 2026SMS Pharmaceuticals Limited announced that they will report Q4, 2026 results on May 22, 2026Valuation Update With 7 Day Price Move • Feb 17Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹368, the stock trades at a trailing P/E ratio of 38.4x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 423% over the past three years.Reported Earnings • Feb 09Third quarter 2026 earnings released: EPS: ₹2.59 (vs ₹2.15 in 3Q 2025)Third quarter 2026 results: EPS: ₹2.59 (up from ₹2.15 in 3Q 2025). Revenue: ₹2.14b (up 24% from 3Q 2025). Net income: ₹234.7m (up 29% from 3Q 2025). Profit margin: 11% (in line with 3Q 2025). Over the last 3 years on average, earnings per share has increased by 62% per year whereas the company’s share price has increased by 63% per year.お知らせ • Jan 31SMS Pharmaceuticals Limited to Report Q3, 2026 Results on Feb 07, 2026SMS Pharmaceuticals Limited announced that they will report Q3, 2026 results at 9:08 AM, Indian Standard Time on Feb 07, 2026Valuation Update With 7 Day Price Move • Dec 01Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₹319, the stock trades at a trailing P/E ratio of 35.4x. Average trailing P/E is 29x in the Pharmaceuticals industry in India. Total returns to shareholders of 276% over the past three years.分析記事 • Nov 16SMS Pharmaceuticals' (NSE:SMSPHARMA) Solid Profits Have Weak FundamentalsDespite posting some strong earnings, the market for SMS Pharmaceuticals Limited's ( NSE:SMSPHARMA ) stock hasn't moved...Reported Earnings • Nov 09Second quarter 2026 earnings released: EPS: ₹2.84 (vs ₹1.67 in 2Q 2025)Second quarter 2026 results: EPS: ₹2.84 (up from ₹1.67 in 2Q 2025). Revenue: ₹2.44b (up 24% from 2Q 2025). Net income: ₹253.1m (up 80% from 2Q 2025). Profit margin: 10% (up from 7.2% in 2Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 73% per year but the company’s share price has only increased by 40% per year, which means it is significantly lagging earnings growth.お知らせ • Nov 03SMS Pharmaceuticals Limited to Report Q2, 2026 Results on Nov 08, 2025SMS Pharmaceuticals Limited announced that they will report Q2, 2026 results at 12:08 PM, Indian Standard Time on Nov 08, 2025New Risk • Oct 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks High level of debt (42% net debt to equity). Share price has been volatile over the past 3 months (6.8% average weekly change).分析記事 • Sep 23We Think Some Shareholders May Hesitate To Increase SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) CEO CompensationKey Insights SMS Pharmaceuticals' Annual General Meeting to take place on 29th of September Salary of ₹30.0m is part of...Upcoming Dividend • Sep 15Upcoming dividend of ₹0.40 per shareEligible shareholders must have bought the stock before 22 September 2025. Payment date: 29 October 2025. Payout ratio is a comfortable 5.1% but the company is not cash flow positive. Trailing yield: 0.1%. Lower than top quartile of Indian dividend payers (1.2%). Lower than average of industry peers (0.7%).分析記事 • Sep 12Market Participants Recognise SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) Earnings Pushing Shares 31% HigherSMS Pharmaceuticals Limited ( NSE:SMSPHARMA ) shares have had a really impressive month, gaining 31% after a shaky...Valuation Update With 7 Day Price Move • Sep 11Investor sentiment improves as stock rises 29%After last week's 29% share price gain to ₹301, the stock trades at a trailing P/E ratio of 36.4x. Average trailing P/E is 31x in the Pharmaceuticals industry in India. Total returns to shareholders of 235% over the past three years.分析記事 • Sep 04SMS Pharmaceuticals (NSE:SMSPHARMA) Has Announced A Dividend Of ₹0.40SMS Pharmaceuticals Limited ( NSE:SMSPHARMA ) has announced that it will pay a dividend of ₹0.40 per share on the 29th...分析記事 • Aug 14SMS Pharmaceuticals (NSE:SMSPHARMA) Is Paying Out A Dividend Of ₹0.40The board of SMS Pharmaceuticals Limited ( NSE:SMSPHARMA ) has announced that it will pay a dividend on the 29th of...Declared Dividend • Aug 13Dividend of ₹0.40 announcedDividend of ₹0.40 is the same as last year. Ex-date: 22nd September 2025 Payment date: 29th October 2025 Dividend yield will be 0.2%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is covered by earnings (5% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 7.2% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. Earnings per share has grown by 18% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.お知らせ • Aug 12SMS Pharmaceuticals Limited announces Annual dividend, payable on October 29, 2025SMS Pharmaceuticals Limited announced Annual dividend of INR 0.4000 per share payable on October 29, 2025, ex-date on September 22, 2025 and record date on September 22, 2025.お知らせ • Aug 11SMS Pharmaceuticals Limited, Annual General Meeting, Sep 29, 2025SMS Pharmaceuticals Limited, Annual General Meeting, Sep 29, 2025.Reported Earnings • Aug 11First quarter 2026 earnings released: EPS: ₹2.31 (vs ₹1.95 in 1Q 2025)First quarter 2026 results: EPS: ₹2.31 (up from ₹1.95 in 1Q 2025). Revenue: ₹1.97b (up 20% from 1Q 2025). Net income: ₹204.9m (up 24% from 1Q 2025). Profit margin: 10% (in line with 1Q 2025). Over the last 3 years on average, earnings per share has increased by 70% per year but the company’s share price has only increased by 37% per year, which means it is significantly lagging earnings growth.New Risk • Aug 10New major risk - Revenue and earnings growthEarnings have declined by 0.4% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 0.4% per year over the past 5 years. Minor Risk High level of debt (42% net debt to equity).お知らせ • Aug 02SMS Pharmaceuticals Limited to Report Q1, 2026 Results on Aug 09, 2025SMS Pharmaceuticals Limited announced that they will report Q1, 2026 results at 12:08 PM, Indian Standard Time on Aug 09, 2025お知らせ • Jun 03SMS Pharmaceuticals Limited Announces Earnings Guidance for the Year 2026SMS Pharmaceuticals Limiteda announced earnings guidance for the year 2026. For the year, the company expects revenue growth of 20%.Reported Earnings • May 31Full year 2025 earnings released: EPS: ₹8.16 (vs ₹5.89 in FY 2024)Full year 2025 results: EPS: ₹8.16 (up from ₹5.89 in FY 2024). Revenue: ₹7.89b (up 11% from FY 2024). Net income: ₹691.4m (up 39% from FY 2024). Profit margin: 8.8% (up from 7.0% in FY 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 47% per year whereas the company’s share price has increased by 48% per year.お知らせ • May 23SMS Pharmaceuticals Limited to Report Q4, 2025 Results on May 30, 2025SMS Pharmaceuticals Limited announced that they will report Q4, 2025 results on May 30, 2025分析記事 • May 14Subdued Growth No Barrier To SMS Pharmaceuticals Limited (NSE:SMSPHARMA) With Shares Advancing 25%SMS Pharmaceuticals Limited ( NSE:SMSPHARMA ) shareholders would be excited to see that the share price has had a great...New Risk • Apr 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 1.8% per year over the past 5 years. Minor Risks High level of debt (49% net debt to equity). Share price has been volatile over the past 3 months (8.8% average weekly change).Valuation Update With 7 Day Price Move • Mar 24Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹218, the stock trades at a trailing P/E ratio of 27.9x. Average trailing P/E is 30x in the Pharmaceuticals industry in India. Total returns to shareholders of 122% over the past three years.分析記事 • Mar 20SMS Pharmaceuticals Limited (NSE:SMSPHARMA) Investors Are Less Pessimistic Than ExpectedThere wouldn't be many who think SMS Pharmaceuticals Limited's ( NSE:SMSPHARMA ) price-to-earnings (or "P/E") ratio of...Reported Earnings • Feb 13Third quarter 2025 earnings released: EPS: ₹2.15 (vs ₹1.36 in 3Q 2024)Third quarter 2025 results: EPS: ₹2.15 (up from ₹1.36 in 3Q 2024). Revenue: ₹1.75b (up 8.7% from 3Q 2024). Net income: ₹182.4m (up 59% from 3Q 2024). Profit margin: 10% (up from 7.1% in 3Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has increased by 25% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Feb 05SMS Pharmaceuticals Limited to Report Q3, 2025 Results on Feb 12, 2025SMS Pharmaceuticals Limited announced that they will report Q3, 2025 results on Feb 12, 2025分析記事 • Jan 11Does SMS Pharmaceuticals (NSE:SMSPHARMA) Have A Healthy Balance Sheet?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...分析記事 • Nov 14Risks Still Elevated At These Prices As SMS Pharmaceuticals Limited (NSE:SMSPHARMA) Shares Dive 25%SMS Pharmaceuticals Limited ( NSE:SMSPHARMA ) shareholders won't be pleased to see that the share price has had a very...Reported Earnings • Nov 09Second quarter 2025 earnings released: EPS: ₹1.67 (vs ₹1.39 in 2Q 2024)Second quarter 2025 results: EPS: ₹1.67 (up from ₹1.39 in 2Q 2024). Revenue: ₹1.98b (up 19% from 2Q 2024). Net income: ₹141.0m (up 20% from 2Q 2024). Profit margin: 7.1% (in line with 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has increased by 29% per year, which means it is well ahead of earnings.お知らせ • Nov 08SMS Pharmaceuticals Limited Approves Reconstitution of CommitteesSMS Pharmaceuticals Limited at its board meeting held on November 8, 2024, approved reconstitution of the Nomination and Remuneration Committee of the Board with effect from November 8, 2024 with the following members: Mrs. Shanti Sree Bolleni, Chairman and Dr. Suresh Kumar Gangavarapu and Dr. Sunkara Venkata Satya Shiva Prasad as Members.お知らせ • Nov 01SMS Pharmaceuticals Limited to Report Q2, 2025 Results on Nov 08, 2024SMS Pharmaceuticals Limited announced that they will report Q2, 2025 results on Nov 08, 2024Valuation Update With 7 Day Price Move • Oct 22Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹290, the stock trades at a trailing P/E ratio of 43.1x. Average trailing P/E is 39x in the Pharmaceuticals industry in India. Total returns to shareholders of 109% over the past three years.Upcoming Dividend • Sep 16Upcoming dividend of ₹0.40 per shareEligible shareholders must have bought the stock before 23 September 2024. Payment date: 30 October 2024. Payout ratio is a comfortable 6.8% but the company is not cash flow positive. Trailing yield: 0.1%. Lower than top quartile of Indian dividend payers (1.0%). Lower than average of industry peers (0.6%).分析記事 • Sep 07SMS Pharmaceuticals (NSE:SMSPHARMA) Has Announced That It Will Be Increasing Its Dividend To ₹0.40SMS Pharmaceuticals Limited ( NSE:SMSPHARMA ) has announced that it will be increasing its dividend from last year's...New Risk • Aug 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 9.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (18% operating cash flow to total debt). Earnings have declined by 7.6% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (9.1% average weekly change).Valuation Update With 7 Day Price Move • Aug 23Investor sentiment improves as stock rises 22%After last week's 22% share price gain to ₹357, the stock trades at a trailing P/E ratio of 53x. Average trailing P/E is 37x in the Pharmaceuticals industry in India. Total returns to shareholders of 113% over the past three years.分析記事 • Aug 22SMS Pharmaceuticals' (NSE:SMSPHARMA) Dividend Will Be Increased To ₹0.40SMS Pharmaceuticals Limited ( NSE:SMSPHARMA ) will increase its dividend from last year's comparable payment on the...分析記事 • Aug 20Earnings Not Telling The Story For SMS Pharmaceuticals Limited (NSE:SMSPHARMA) After Shares Rise 27%SMS Pharmaceuticals Limited ( NSE:SMSPHARMA ) shares have continued their recent momentum with a 27% gain in the last...分析記事 • Aug 08SMS Pharmaceuticals (NSE:SMSPHARMA) Has Announced That It Will Be Increasing Its Dividend To ₹0.40The board of SMS Pharmaceuticals Limited ( NSE:SMSPHARMA ) has announced that it will be paying its dividend of ₹0.40...Declared Dividend • Aug 07Dividend increased to ₹0.40Dividend of ₹0.40 is 33% higher than last year. Ex-date: 23rd September 2024 Payment date: 30th October 2024 Dividend yield will be 0.1%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is covered by earnings (7% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 7.2% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. Earnings per share has grown by 7.0% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.Reported Earnings • Aug 06First quarter 2025 earnings released: EPS: ₹1.95 (vs ₹1.10 in 1Q 2024)First quarter 2025 results: EPS: ₹1.95 (up from ₹1.10 in 1Q 2024). Revenue: ₹1.64b (up 22% from 1Q 2024). Net income: ₹164.8m (up 76% from 1Q 2024). Profit margin: 10.0% (up from 6.9% in 1Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 34% per year but the company’s share price has increased by 16% per year, which means it is well ahead of earnings.お知らせ • Aug 05+ 1 more updateSMS Pharmaceuticals Limited, Annual General Meeting, Sep 30, 2024SMS Pharmaceuticals Limited, Annual General Meeting, Sep 30, 2024.お知らせ • Jul 29SMS Pharmaceuticals Limited to Report Q1, 2025 Results on Aug 05, 2024SMS Pharmaceuticals Limited announced that they will report Q1, 2025 results on Aug 05, 2024Valuation Update With 7 Day Price Move • Jul 25Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹277, the stock trades at a trailing P/E ratio of 47x. Average trailing P/E is 36x in the Pharmaceuticals industry in India. Total returns to shareholders of 56% over the past three years.Valuation Update With 7 Day Price Move • Jul 05Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹260, the stock trades at a trailing P/E ratio of 44.2x. Average trailing P/E is 34x in the Pharmaceuticals industry in India. Total returns to shareholders of 48% over the past three years.分析記事 • Jul 04What SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) 27% Share Price Gain Is Not Telling YouSMS Pharmaceuticals Limited ( NSE:SMSPHARMA ) shareholders have had their patience rewarded with a 27% share price jump...分析記事 • Jun 21Here's Why SMS Pharmaceuticals (NSE:SMSPHARMA) Can Manage Its Debt ResponsiblyThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...お知らせ • May 31SMS Pharmaceuticals Limited Recommends Dividend for the Financial Year 2023-2024SMS Pharmaceuticals Limited announced that at its board meeting held on 29 May 2024, recommended the dividend of INR 0.40 (40%) per equity share of face value of INR 1 each for the financial year 2023-2024, subject To Approve the members at the upcoming Annual General Meeting (AGM). The AGM date and book closure /record date for the purpose of the payment of dividend will be informed in due course.Reported Earnings • May 30Full year 2024 earnings released: EPS: ₹5.89 (vs ₹0.83 loss in FY 2023)Full year 2024 results: EPS: ₹5.89 (up from ₹0.83 loss in FY 2023). Revenue: ₹7.14b (up 37% from FY 2023). Net income: ₹498.3m (up ₹568.9m from FY 2023). Profit margin: 7.0% (up from net loss in FY 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 48% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings.お知らせ • May 24SMS Pharmaceuticals Limited to Report Q4, 2024 Results on May 29, 2024SMS Pharmaceuticals Limited announced that they will report Q4, 2024 results on May 29, 2024Valuation Update With 7 Day Price Move • Apr 05Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹206, the stock trades at a trailing P/E ratio of 48.4x. Average trailing P/E is 33x in the Pharmaceuticals industry in India. Total returns to shareholders of 41% over the past three years.お知らせ • Mar 19SMS Pharmaceuticals Limited announced that it has received INR 285.75 million in funding from Potluri Infra Projects Private LimitedOn March 19, 2024, SMS Pharmaceuticals Limited, closed the transaction.New Risk • Mar 12New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 14% per year over the past 5 years. Minor Risks High level of debt (51% net debt to equity). Share price has been volatile over the past 3 months (8.3% average weekly change).Valuation Update With 7 Day Price Move • Mar 05Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹182, the stock trades at a trailing P/E ratio of 42.7x. Average trailing P/E is 34x in the Pharmaceuticals industry in India. Total returns to shareholders of 42% over the past three years.分析記事 • Feb 29SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) 25% Share Price Surge Not Quite Adding UpThe SMS Pharmaceuticals Limited ( NSE:SMSPHARMA ) share price has done very well over the last month, posting an...お知らせ • Feb 09SMS Pharmaceuticals Limited announced that it expects to receive INR 285.75 million in funding from Potluri Infra Projects Private LimitedSMS Pharmaceuticals Limited announced a private placement of 9,000,000 common shares at a price of INR 31.75 per share for the gross proceeds of INR 285,750,000 on February 8, 2024. The transaction will include participation from new investor, Potluri Infra Projects Private Limited for 1,500,000 warrants, individual investors, Ramesh Babu Potluri for 2,500,000 warrants, Vamsi Krishna Potluri for 2,500,000 warrants, Trilok Potluri for 2,500,000 warrants. The transaction has been approved by the shareholders of the company.Reported Earnings • Feb 09Third quarter 2024 earnings released: EPS: ₹1.36 (vs ₹0.44 in 3Q 2023)Third quarter 2024 results: EPS: ₹1.36 (up from ₹0.44 in 3Q 2023). Revenue: ₹1.63b (up 9.5% from 3Q 2023). Net income: ₹114.8m (up 205% from 3Q 2023). Profit margin: 7.0% (up from 2.5% in 3Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 54% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings.お知らせ • Feb 03SMS Pharmaceuticals Limited to Report Q3, 2024 Results on Feb 08, 2024SMS Pharmaceuticals Limited announced that they will report Q3, 2024 results on Feb 08, 2024Reported Earnings • Nov 10Second quarter 2024 earnings released: EPS: ₹1.39 (vs ₹0.24 loss in 2Q 2023)Second quarter 2024 results: EPS: ₹1.39 (up from ₹0.24 loss in 2Q 2023). Revenue: ₹1.67b (up 5.0% from 2Q 2023). Net income: ₹117.3m (up ₹137.3m from 2Q 2023). Profit margin: 7.0% (up from net loss in 2Q 2023). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 54% per year but the company’s share price has increased by 12% per year, which means it is well ahead of earnings.お知らせ • Nov 03SMS Pharmaceuticals Limited to Report Q2, 2024 Results on Nov 08, 2023SMS Pharmaceuticals Limited announced that they will report Q2, 2024 results on Nov 08, 2023分析記事 • Sep 24SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) CEO Compensation Is Looking A Bit Stretched At The MomentKey Insights SMS Pharmaceuticals will host its Annual General Meeting on 30th of September Total pay for CEO Ramesh...Upcoming Dividend • Sep 15Upcoming dividend of ₹0.30 per share at 0.2% yieldEligible shareholders must have bought the stock before 22 September 2023. Payment date: 29 October 2023. The company is not currently making a profit and is not cash flow positive. Trailing yield: 0.2%. Lower than top quartile of Indian dividend payers (1.3%). Lower than average of industry peers (0.9%).分析記事 • Sep 11SMS Pharmaceuticals' (NSE:SMSPHARMA) Dividend Will Be ₹0.30The board of SMS Pharmaceuticals Limited ( NSE:SMSPHARMA ) has announced that it will pay a dividend of ₹0.30 per share...分析記事 • Aug 28SMS Pharmaceuticals (NSE:SMSPHARMA) Has Announced A Dividend Of ₹0.30SMS Pharmaceuticals Limited ( NSE:SMSPHARMA ) will pay a dividend of ₹0.30 on the 29th of October. This payment means...お知らせ • Aug 09SMS Pharmaceuticals Limited, Annual General Meeting, Sep 30, 2023SMS Pharmaceuticals Limited, Annual General Meeting, Sep 30, 2023.Reported Earnings • Aug 09First quarter 2024 earnings released: EPS: ₹1.10 (vs ₹1.51 loss in 1Q 2023)First quarter 2024 results: EPS: ₹1.10 (up from ₹1.51 loss in 1Q 2023). Revenue: ₹1.36b (up 111% from 1Q 2023). Net income: ₹93.4m (up ₹221.1m from 1Q 2023). Profit margin: 6.9% (up from net loss in 1Q 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 43% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings.お知らせ • Aug 03SMS Pharmaceuticals Limited to Report Q1, 2024 Results on Aug 08, 2023SMS Pharmaceuticals Limited announced that they will report Q1, 2024 results on Aug 08, 2023Board Change • Jul 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 3 highly experienced directors. Executive Director Vamsi Potluri was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.分析記事 • Jun 07SMS Pharmaceuticals (NSE:SMSPHARMA) Has A Somewhat Strained Balance SheetDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Reported Earnings • May 26Full year 2023 earnings released: ₹0.83 loss per share (vs ₹7.35 profit in FY 2022)Full year 2023 results: ₹0.83 loss per share (down from ₹7.35 profit in FY 2022). Revenue: ₹5.27b (up 1.4% from FY 2022). Net loss: ₹70.6m (down 111% from profit in FY 2022). Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has increased by 28% per year, which means it is well ahead of earnings.お知らせ • May 25SMS Pharmaceuticals Limited Recommends Dividend for the Financial Year 2022-2023The board of directors of SMS Pharmaceuticals Limited at its AGM held on May 24, 2023, recommended the Dividend of INR 0.30 (30%) per equity share of face value of INR 1.00 each for the financial year 2022-23, subject To Approve the members at the upcoming annual general meeting. The AGM date and book closure/record date for the purpose of the payment of dividend will be informed in due course.お知らせ • May 19SMS Pharmaceuticals Limited to Report Q4, 2023 Results on May 24, 2023SMS Pharmaceuticals Limited announced that they will report Q4, 2023 results at 12:08 PM, Indian Standard Time on May 24, 2023Reported Earnings • Feb 10Third quarter 2023 earnings released: EPS: ₹0.44 (vs ₹1.07 in 3Q 2022)Third quarter 2023 results: EPS: ₹0.44 (down from ₹1.07 in 3Q 2022). Revenue: ₹1.51b (up 22% from 3Q 2022). Net income: ₹37.6m (down 58% from 3Q 2022). Profit margin: 2.5% (down from 7.3% in 3Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has increased by 22% per year, which means it is well ahead of earnings.お知らせ • Feb 01SMS Pharmaceuticals Limited to Report Q3, 2023 Results on Feb 09, 2023SMS Pharmaceuticals Limited announced that they will report Q3, 2023 results on Feb 09, 2023Reported Earnings • Nov 16Second quarter 2023 earnings released: ₹0.24 loss per share (vs ₹2.72 profit in 2Q 2022)Second quarter 2023 results: ₹0.24 loss per share (down from ₹2.72 profit in 2Q 2022). Revenue: ₹1.60b (down 9.1% from 2Q 2022). Net loss: ₹20.1m (down 109% from profit in 2Q 2022). Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has increased by 30% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • Nov 11Investor sentiment improved over the past weekAfter last week's 18% share price gain to ₹105, the stock trades at a trailing P/E ratio of 34.5x. Average trailing P/E is 25x in the Pharmaceuticals industry in India. Total returns to shareholders of 165% over the past three years.分析記事 • Sep 23Shareholders May Not Be So Generous With SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) CEO Compensation And Here's WhySMS Pharmaceuticals Limited ( NSE:SMSPHARMA ) has exhibited strong share price growth in the past few years. However...Upcoming Dividend • Sep 15Upcoming dividend of ₹0.30 per shareEligible shareholders must have bought the stock before 22 September 2022. Payment date: 30 October 2022. Payout ratio is a comfortable 9.8% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of Indian dividend payers (1.5%). Lower than average of industry peers (1.0%).分析記事 • Sep 15SMS Pharmaceuticals (NSE:SMSPHARMA) Is Due To Pay A Dividend Of ₹0.30The board of SMS Pharmaceuticals Limited ( NSE:SMSPHARMA ) has announced that it will pay a dividend on the 30th of...分析記事 • Sep 01SMS Pharmaceuticals (NSE:SMSPHARMA) Will Pay A Dividend Of ₹0.30SMS Pharmaceuticals Limited ( NSE:SMSPHARMA ) has announced that it will pay a dividend of ₹0.30 per share on the 30th...Reported Earnings • Aug 18First quarter 2023 earnings released: ₹1.51 loss per share (vs ₹2.78 profit in 1Q 2022)First quarter 2023 results: ₹1.51 loss per share (down from ₹2.78 profit in 1Q 2022). Revenue: ₹651.9m (down 60% from 1Q 2022). Net loss: ₹127.7m (down 154% from profit in 1Q 2022). Over the last 3 years on average, earnings per share has increased by 21% per year whereas the company’s share price has increased by 23% per year.分析記事 • Aug 18SMS Pharmaceuticals (NSE:SMSPHARMA) Has Announced A Dividend Of ₹0.30The board of SMS Pharmaceuticals Limited ( NSE:SMSPHARMA ) has announced that it will pay a dividend on the 30th of...Reported Earnings • Jun 02Full year 2022 earnings released: EPS: ₹7.35 (vs ₹7.39 in FY 2021)Full year 2022 results: EPS: ₹7.35 (down from ₹7.39 in FY 2021). Revenue: ₹5.25b (down 7.1% from FY 2021). Net income: ₹622.2m (flat on FY 2021). Profit margin: 12% (in line with FY 2021). Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Mar 22Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₹112, the stock trades at a trailing P/E ratio of 12x. Average trailing P/E is 25x in the Pharmaceuticals industry in India. Total returns to shareholders of 78% over the past three years.分析記事 • Mar 22We Think SMS Pharmaceuticals (NSE:SMSPHARMA) Can Stay On Top Of Its DebtThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Reported Earnings • Feb 10Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: EPS: ₹1.07 (down from ₹2.53 in 3Q 2021). Revenue: ₹1.23b (down 18% from 3Q 2021). Net income: ₹89.6m (down 58% from 3Q 2021). Profit margin: 7.3% (down from 14% in 3Q 2021). The decrease in margin was driven by lower revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has only increased by 20% per year, which means it is significantly lagging earnings growth.Reported Earnings • Nov 15Second quarter 2022 earnings released: EPS ₹2.72 (vs ₹1.30 in 2Q 2021)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2022 results: Revenue: ₹1.76b (up 34% from 2Q 2021). Net income: ₹230.3m (up 110% from 2Q 2021). Profit margin: 13% (up from 8.4% in 2Q 2021). The increase in margin was driven by higher revenue.Upcoming Dividend • Sep 15Upcoming dividend of ₹0.30 per shareEligible shareholders must have bought the stock before 22 September 2021. Payment date: 30 October 2021. Trailing yield: 0.2%. Lower than top quartile of Indian dividend payers (1.5%). Lower than average of industry peers (0.7%).Reported Earnings • Aug 09First quarter 2022 earnings released: EPS ₹2.78 (vs ₹0.83 in 1Q 2021)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2022 results: Revenue: ₹1.64b (up 45% from 1Q 2021). Net income: ₹235.6m (up 235% from 1Q 2021). Profit margin: 14% (up from 6.2% in 1Q 2021). The increase in margin was driven by higher revenue.Valuation Update With 7 Day Price Move • Jun 14Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹184, the stock trades at a trailing P/E ratio of 24.6x. Average trailing P/E is 24x in the Pharmaceuticals industry in India. Total returns to shareholders of 143% over the past three years.株主還元SMSPHARMAIN PharmaceuticalsIN 市場7D0.5%1.1%-1.0%1Y50.2%10.2%-2.4%株主還元を見る業界別リターン: SMSPHARMA過去 1 年間で10.2 % の収益を上げたIndian Pharmaceuticals業界を上回りました。リターン対市場: SMSPHARMA過去 1 年間で-2.4 % の収益を上げたIndian市場を上回りました。価格変動Is SMSPHARMA's price volatile compared to industry and market?SMSPHARMA volatilitySMSPHARMA Average Weekly Movement5.9%Pharmaceuticals Industry Average Movement7.1%Market Average Movement6.8%10% most volatile stocks in IN Market9.9%10% least volatile stocks in IN Market4.4%安定した株価: SMSPHARMA 、 Indian市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: SMSPHARMAの 週次ボラティリティ ( 6% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト19871,470Ramesh Potlurismspharma.comエス・エム・エス・ファーマシューティカルズ社は、医薬品原薬（API）とその中間体の製造・販売をインド国内外で行っている。抗レトロウイルス薬、抗炎症薬、抗ウイルス薬、抗糖尿病薬、抗真菌薬、抗てんかん薬、抗偏頭痛薬、抗凝固薬、抗精神病薬、抗狭心症薬、抗潰瘍薬などを提供している。また、ペプチドの受託研究活動も行っている。約75カ国に製品を輸出している。エス・エム・エス・ファーマシューティカルズ社は1987年に設立され、本社はインドのハイデラバードにある。もっと見るSMS Pharmaceuticals Limited 基礎のまとめSMS Pharmaceuticals の収益と売上を時価総額と比較するとどうか。SMSPHARMA 基礎統計学時価総額₹35.26b収益（TTM）₹1.02b売上高(TTM)₹8.87b34.6xPER（株価収益率4.0xP/SレシオSMSPHARMA は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計SMSPHARMA 損益計算書（TTM）収益₹8.87b売上原価₹5.84b売上総利益₹3.03bその他の費用₹2.01b収益₹1.02b直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）10.89グロス・マージン34.15%純利益率11.50%有利子負債／自己資本比率46.5%SMSPHARMA の長期的なパフォーマンスは？過去の実績と比較を見る配当金0.1%現在の配当利回り4%配当性向View Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/29 06:02終値2026/06/25 00:00収益2026/03/31年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋SMS Pharmaceuticals Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Anil BurraFirstCall Research
分析記事 • May 31SMS Pharmaceuticals' (NSE:SMSPHARMA) Earnings Are Of Questionable QualityInvestors were disappointed with SMS Pharmaceuticals Limited's ( NSE:SMSPHARMA ) earnings, despite the strong profit...
分析記事 • May 28With EPS Growth And More, SMS Pharmaceuticals (NSE:SMSPHARMA) Makes An Interesting CaseIt's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...
New Risk • May 23New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 16% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. This is currently the only risk that has been identified for the company.
Reported Earnings • May 23Full year 2026 earnings released: EPS: ₹11.15 (vs ₹7.80 in FY 2025)Full year 2026 results: EPS: ₹11.15 (up from ₹7.80 in FY 2025). Revenue: ₹8.95b (up 14% from FY 2025). Net income: ₹1.02b (up 48% from FY 2025). Profit margin: 11% (up from 8.8% in FY 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has increased by 65% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • May 16SMS Pharmaceuticals Limited to Report Q4, 2026 Results on May 22, 2026SMS Pharmaceuticals Limited announced that they will report Q4, 2026 results on May 22, 2026
Valuation Update With 7 Day Price Move • Feb 17Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹368, the stock trades at a trailing P/E ratio of 38.4x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 423% over the past three years.
分析記事 • May 31SMS Pharmaceuticals' (NSE:SMSPHARMA) Earnings Are Of Questionable QualityInvestors were disappointed with SMS Pharmaceuticals Limited's ( NSE:SMSPHARMA ) earnings, despite the strong profit...
分析記事 • May 28With EPS Growth And More, SMS Pharmaceuticals (NSE:SMSPHARMA) Makes An Interesting CaseIt's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...
New Risk • May 23New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 16% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. This is currently the only risk that has been identified for the company.
Reported Earnings • May 23Full year 2026 earnings released: EPS: ₹11.15 (vs ₹7.80 in FY 2025)Full year 2026 results: EPS: ₹11.15 (up from ₹7.80 in FY 2025). Revenue: ₹8.95b (up 14% from FY 2025). Net income: ₹1.02b (up 48% from FY 2025). Profit margin: 11% (up from 8.8% in FY 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has increased by 65% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • May 16SMS Pharmaceuticals Limited to Report Q4, 2026 Results on May 22, 2026SMS Pharmaceuticals Limited announced that they will report Q4, 2026 results on May 22, 2026
Valuation Update With 7 Day Price Move • Feb 17Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹368, the stock trades at a trailing P/E ratio of 38.4x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 423% over the past three years.
Reported Earnings • Feb 09Third quarter 2026 earnings released: EPS: ₹2.59 (vs ₹2.15 in 3Q 2025)Third quarter 2026 results: EPS: ₹2.59 (up from ₹2.15 in 3Q 2025). Revenue: ₹2.14b (up 24% from 3Q 2025). Net income: ₹234.7m (up 29% from 3Q 2025). Profit margin: 11% (in line with 3Q 2025). Over the last 3 years on average, earnings per share has increased by 62% per year whereas the company’s share price has increased by 63% per year.
お知らせ • Jan 31SMS Pharmaceuticals Limited to Report Q3, 2026 Results on Feb 07, 2026SMS Pharmaceuticals Limited announced that they will report Q3, 2026 results at 9:08 AM, Indian Standard Time on Feb 07, 2026
Valuation Update With 7 Day Price Move • Dec 01Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₹319, the stock trades at a trailing P/E ratio of 35.4x. Average trailing P/E is 29x in the Pharmaceuticals industry in India. Total returns to shareholders of 276% over the past three years.
分析記事 • Nov 16SMS Pharmaceuticals' (NSE:SMSPHARMA) Solid Profits Have Weak FundamentalsDespite posting some strong earnings, the market for SMS Pharmaceuticals Limited's ( NSE:SMSPHARMA ) stock hasn't moved...
Reported Earnings • Nov 09Second quarter 2026 earnings released: EPS: ₹2.84 (vs ₹1.67 in 2Q 2025)Second quarter 2026 results: EPS: ₹2.84 (up from ₹1.67 in 2Q 2025). Revenue: ₹2.44b (up 24% from 2Q 2025). Net income: ₹253.1m (up 80% from 2Q 2025). Profit margin: 10% (up from 7.2% in 2Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 73% per year but the company’s share price has only increased by 40% per year, which means it is significantly lagging earnings growth.
お知らせ • Nov 03SMS Pharmaceuticals Limited to Report Q2, 2026 Results on Nov 08, 2025SMS Pharmaceuticals Limited announced that they will report Q2, 2026 results at 12:08 PM, Indian Standard Time on Nov 08, 2025
New Risk • Oct 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks High level of debt (42% net debt to equity). Share price has been volatile over the past 3 months (6.8% average weekly change).
分析記事 • Sep 23We Think Some Shareholders May Hesitate To Increase SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) CEO CompensationKey Insights SMS Pharmaceuticals' Annual General Meeting to take place on 29th of September Salary of ₹30.0m is part of...
Upcoming Dividend • Sep 15Upcoming dividend of ₹0.40 per shareEligible shareholders must have bought the stock before 22 September 2025. Payment date: 29 October 2025. Payout ratio is a comfortable 5.1% but the company is not cash flow positive. Trailing yield: 0.1%. Lower than top quartile of Indian dividend payers (1.2%). Lower than average of industry peers (0.7%).
分析記事 • Sep 12Market Participants Recognise SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) Earnings Pushing Shares 31% HigherSMS Pharmaceuticals Limited ( NSE:SMSPHARMA ) shares have had a really impressive month, gaining 31% after a shaky...
Valuation Update With 7 Day Price Move • Sep 11Investor sentiment improves as stock rises 29%After last week's 29% share price gain to ₹301, the stock trades at a trailing P/E ratio of 36.4x. Average trailing P/E is 31x in the Pharmaceuticals industry in India. Total returns to shareholders of 235% over the past three years.
分析記事 • Sep 04SMS Pharmaceuticals (NSE:SMSPHARMA) Has Announced A Dividend Of ₹0.40SMS Pharmaceuticals Limited ( NSE:SMSPHARMA ) has announced that it will pay a dividend of ₹0.40 per share on the 29th...
分析記事 • Aug 14SMS Pharmaceuticals (NSE:SMSPHARMA) Is Paying Out A Dividend Of ₹0.40The board of SMS Pharmaceuticals Limited ( NSE:SMSPHARMA ) has announced that it will pay a dividend on the 29th of...
Declared Dividend • Aug 13Dividend of ₹0.40 announcedDividend of ₹0.40 is the same as last year. Ex-date: 22nd September 2025 Payment date: 29th October 2025 Dividend yield will be 0.2%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is covered by earnings (5% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 7.2% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. Earnings per share has grown by 18% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.
お知らせ • Aug 12SMS Pharmaceuticals Limited announces Annual dividend, payable on October 29, 2025SMS Pharmaceuticals Limited announced Annual dividend of INR 0.4000 per share payable on October 29, 2025, ex-date on September 22, 2025 and record date on September 22, 2025.
お知らせ • Aug 11SMS Pharmaceuticals Limited, Annual General Meeting, Sep 29, 2025SMS Pharmaceuticals Limited, Annual General Meeting, Sep 29, 2025.
Reported Earnings • Aug 11First quarter 2026 earnings released: EPS: ₹2.31 (vs ₹1.95 in 1Q 2025)First quarter 2026 results: EPS: ₹2.31 (up from ₹1.95 in 1Q 2025). Revenue: ₹1.97b (up 20% from 1Q 2025). Net income: ₹204.9m (up 24% from 1Q 2025). Profit margin: 10% (in line with 1Q 2025). Over the last 3 years on average, earnings per share has increased by 70% per year but the company’s share price has only increased by 37% per year, which means it is significantly lagging earnings growth.
New Risk • Aug 10New major risk - Revenue and earnings growthEarnings have declined by 0.4% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 0.4% per year over the past 5 years. Minor Risk High level of debt (42% net debt to equity).
お知らせ • Aug 02SMS Pharmaceuticals Limited to Report Q1, 2026 Results on Aug 09, 2025SMS Pharmaceuticals Limited announced that they will report Q1, 2026 results at 12:08 PM, Indian Standard Time on Aug 09, 2025
お知らせ • Jun 03SMS Pharmaceuticals Limited Announces Earnings Guidance for the Year 2026SMS Pharmaceuticals Limiteda announced earnings guidance for the year 2026. For the year, the company expects revenue growth of 20%.
Reported Earnings • May 31Full year 2025 earnings released: EPS: ₹8.16 (vs ₹5.89 in FY 2024)Full year 2025 results: EPS: ₹8.16 (up from ₹5.89 in FY 2024). Revenue: ₹7.89b (up 11% from FY 2024). Net income: ₹691.4m (up 39% from FY 2024). Profit margin: 8.8% (up from 7.0% in FY 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 47% per year whereas the company’s share price has increased by 48% per year.
お知らせ • May 23SMS Pharmaceuticals Limited to Report Q4, 2025 Results on May 30, 2025SMS Pharmaceuticals Limited announced that they will report Q4, 2025 results on May 30, 2025
分析記事 • May 14Subdued Growth No Barrier To SMS Pharmaceuticals Limited (NSE:SMSPHARMA) With Shares Advancing 25%SMS Pharmaceuticals Limited ( NSE:SMSPHARMA ) shareholders would be excited to see that the share price has had a great...
New Risk • Apr 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 1.8% per year over the past 5 years. Minor Risks High level of debt (49% net debt to equity). Share price has been volatile over the past 3 months (8.8% average weekly change).
Valuation Update With 7 Day Price Move • Mar 24Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹218, the stock trades at a trailing P/E ratio of 27.9x. Average trailing P/E is 30x in the Pharmaceuticals industry in India. Total returns to shareholders of 122% over the past three years.
分析記事 • Mar 20SMS Pharmaceuticals Limited (NSE:SMSPHARMA) Investors Are Less Pessimistic Than ExpectedThere wouldn't be many who think SMS Pharmaceuticals Limited's ( NSE:SMSPHARMA ) price-to-earnings (or "P/E") ratio of...
Reported Earnings • Feb 13Third quarter 2025 earnings released: EPS: ₹2.15 (vs ₹1.36 in 3Q 2024)Third quarter 2025 results: EPS: ₹2.15 (up from ₹1.36 in 3Q 2024). Revenue: ₹1.75b (up 8.7% from 3Q 2024). Net income: ₹182.4m (up 59% from 3Q 2024). Profit margin: 10% (up from 7.1% in 3Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has increased by 25% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Feb 05SMS Pharmaceuticals Limited to Report Q3, 2025 Results on Feb 12, 2025SMS Pharmaceuticals Limited announced that they will report Q3, 2025 results on Feb 12, 2025
分析記事 • Jan 11Does SMS Pharmaceuticals (NSE:SMSPHARMA) Have A Healthy Balance Sheet?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
分析記事 • Nov 14Risks Still Elevated At These Prices As SMS Pharmaceuticals Limited (NSE:SMSPHARMA) Shares Dive 25%SMS Pharmaceuticals Limited ( NSE:SMSPHARMA ) shareholders won't be pleased to see that the share price has had a very...
Reported Earnings • Nov 09Second quarter 2025 earnings released: EPS: ₹1.67 (vs ₹1.39 in 2Q 2024)Second quarter 2025 results: EPS: ₹1.67 (up from ₹1.39 in 2Q 2024). Revenue: ₹1.98b (up 19% from 2Q 2024). Net income: ₹141.0m (up 20% from 2Q 2024). Profit margin: 7.1% (in line with 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has increased by 29% per year, which means it is well ahead of earnings.
お知らせ • Nov 08SMS Pharmaceuticals Limited Approves Reconstitution of CommitteesSMS Pharmaceuticals Limited at its board meeting held on November 8, 2024, approved reconstitution of the Nomination and Remuneration Committee of the Board with effect from November 8, 2024 with the following members: Mrs. Shanti Sree Bolleni, Chairman and Dr. Suresh Kumar Gangavarapu and Dr. Sunkara Venkata Satya Shiva Prasad as Members.
お知らせ • Nov 01SMS Pharmaceuticals Limited to Report Q2, 2025 Results on Nov 08, 2024SMS Pharmaceuticals Limited announced that they will report Q2, 2025 results on Nov 08, 2024
Valuation Update With 7 Day Price Move • Oct 22Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹290, the stock trades at a trailing P/E ratio of 43.1x. Average trailing P/E is 39x in the Pharmaceuticals industry in India. Total returns to shareholders of 109% over the past three years.
Upcoming Dividend • Sep 16Upcoming dividend of ₹0.40 per shareEligible shareholders must have bought the stock before 23 September 2024. Payment date: 30 October 2024. Payout ratio is a comfortable 6.8% but the company is not cash flow positive. Trailing yield: 0.1%. Lower than top quartile of Indian dividend payers (1.0%). Lower than average of industry peers (0.6%).
分析記事 • Sep 07SMS Pharmaceuticals (NSE:SMSPHARMA) Has Announced That It Will Be Increasing Its Dividend To ₹0.40SMS Pharmaceuticals Limited ( NSE:SMSPHARMA ) has announced that it will be increasing its dividend from last year's...
New Risk • Aug 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 9.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (18% operating cash flow to total debt). Earnings have declined by 7.6% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (9.1% average weekly change).
Valuation Update With 7 Day Price Move • Aug 23Investor sentiment improves as stock rises 22%After last week's 22% share price gain to ₹357, the stock trades at a trailing P/E ratio of 53x. Average trailing P/E is 37x in the Pharmaceuticals industry in India. Total returns to shareholders of 113% over the past three years.
分析記事 • Aug 22SMS Pharmaceuticals' (NSE:SMSPHARMA) Dividend Will Be Increased To ₹0.40SMS Pharmaceuticals Limited ( NSE:SMSPHARMA ) will increase its dividend from last year's comparable payment on the...
分析記事 • Aug 20Earnings Not Telling The Story For SMS Pharmaceuticals Limited (NSE:SMSPHARMA) After Shares Rise 27%SMS Pharmaceuticals Limited ( NSE:SMSPHARMA ) shares have continued their recent momentum with a 27% gain in the last...
分析記事 • Aug 08SMS Pharmaceuticals (NSE:SMSPHARMA) Has Announced That It Will Be Increasing Its Dividend To ₹0.40The board of SMS Pharmaceuticals Limited ( NSE:SMSPHARMA ) has announced that it will be paying its dividend of ₹0.40...
Declared Dividend • Aug 07Dividend increased to ₹0.40Dividend of ₹0.40 is 33% higher than last year. Ex-date: 23rd September 2024 Payment date: 30th October 2024 Dividend yield will be 0.1%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is covered by earnings (7% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 7.2% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. Earnings per share has grown by 7.0% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.
Reported Earnings • Aug 06First quarter 2025 earnings released: EPS: ₹1.95 (vs ₹1.10 in 1Q 2024)First quarter 2025 results: EPS: ₹1.95 (up from ₹1.10 in 1Q 2024). Revenue: ₹1.64b (up 22% from 1Q 2024). Net income: ₹164.8m (up 76% from 1Q 2024). Profit margin: 10.0% (up from 6.9% in 1Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 34% per year but the company’s share price has increased by 16% per year, which means it is well ahead of earnings.
お知らせ • Aug 05+ 1 more updateSMS Pharmaceuticals Limited, Annual General Meeting, Sep 30, 2024SMS Pharmaceuticals Limited, Annual General Meeting, Sep 30, 2024.
お知らせ • Jul 29SMS Pharmaceuticals Limited to Report Q1, 2025 Results on Aug 05, 2024SMS Pharmaceuticals Limited announced that they will report Q1, 2025 results on Aug 05, 2024
Valuation Update With 7 Day Price Move • Jul 25Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹277, the stock trades at a trailing P/E ratio of 47x. Average trailing P/E is 36x in the Pharmaceuticals industry in India. Total returns to shareholders of 56% over the past three years.
Valuation Update With 7 Day Price Move • Jul 05Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹260, the stock trades at a trailing P/E ratio of 44.2x. Average trailing P/E is 34x in the Pharmaceuticals industry in India. Total returns to shareholders of 48% over the past three years.
分析記事 • Jul 04What SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) 27% Share Price Gain Is Not Telling YouSMS Pharmaceuticals Limited ( NSE:SMSPHARMA ) shareholders have had their patience rewarded with a 27% share price jump...
分析記事 • Jun 21Here's Why SMS Pharmaceuticals (NSE:SMSPHARMA) Can Manage Its Debt ResponsiblyThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
お知らせ • May 31SMS Pharmaceuticals Limited Recommends Dividend for the Financial Year 2023-2024SMS Pharmaceuticals Limited announced that at its board meeting held on 29 May 2024, recommended the dividend of INR 0.40 (40%) per equity share of face value of INR 1 each for the financial year 2023-2024, subject To Approve the members at the upcoming Annual General Meeting (AGM). The AGM date and book closure /record date for the purpose of the payment of dividend will be informed in due course.
Reported Earnings • May 30Full year 2024 earnings released: EPS: ₹5.89 (vs ₹0.83 loss in FY 2023)Full year 2024 results: EPS: ₹5.89 (up from ₹0.83 loss in FY 2023). Revenue: ₹7.14b (up 37% from FY 2023). Net income: ₹498.3m (up ₹568.9m from FY 2023). Profit margin: 7.0% (up from net loss in FY 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 48% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings.
お知らせ • May 24SMS Pharmaceuticals Limited to Report Q4, 2024 Results on May 29, 2024SMS Pharmaceuticals Limited announced that they will report Q4, 2024 results on May 29, 2024
Valuation Update With 7 Day Price Move • Apr 05Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹206, the stock trades at a trailing P/E ratio of 48.4x. Average trailing P/E is 33x in the Pharmaceuticals industry in India. Total returns to shareholders of 41% over the past three years.
お知らせ • Mar 19SMS Pharmaceuticals Limited announced that it has received INR 285.75 million in funding from Potluri Infra Projects Private LimitedOn March 19, 2024, SMS Pharmaceuticals Limited, closed the transaction.
New Risk • Mar 12New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 14% per year over the past 5 years. Minor Risks High level of debt (51% net debt to equity). Share price has been volatile over the past 3 months (8.3% average weekly change).
Valuation Update With 7 Day Price Move • Mar 05Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹182, the stock trades at a trailing P/E ratio of 42.7x. Average trailing P/E is 34x in the Pharmaceuticals industry in India. Total returns to shareholders of 42% over the past three years.
分析記事 • Feb 29SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) 25% Share Price Surge Not Quite Adding UpThe SMS Pharmaceuticals Limited ( NSE:SMSPHARMA ) share price has done very well over the last month, posting an...
お知らせ • Feb 09SMS Pharmaceuticals Limited announced that it expects to receive INR 285.75 million in funding from Potluri Infra Projects Private LimitedSMS Pharmaceuticals Limited announced a private placement of 9,000,000 common shares at a price of INR 31.75 per share for the gross proceeds of INR 285,750,000 on February 8, 2024. The transaction will include participation from new investor, Potluri Infra Projects Private Limited for 1,500,000 warrants, individual investors, Ramesh Babu Potluri for 2,500,000 warrants, Vamsi Krishna Potluri for 2,500,000 warrants, Trilok Potluri for 2,500,000 warrants. The transaction has been approved by the shareholders of the company.
Reported Earnings • Feb 09Third quarter 2024 earnings released: EPS: ₹1.36 (vs ₹0.44 in 3Q 2023)Third quarter 2024 results: EPS: ₹1.36 (up from ₹0.44 in 3Q 2023). Revenue: ₹1.63b (up 9.5% from 3Q 2023). Net income: ₹114.8m (up 205% from 3Q 2023). Profit margin: 7.0% (up from 2.5% in 3Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 54% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings.
お知らせ • Feb 03SMS Pharmaceuticals Limited to Report Q3, 2024 Results on Feb 08, 2024SMS Pharmaceuticals Limited announced that they will report Q3, 2024 results on Feb 08, 2024
Reported Earnings • Nov 10Second quarter 2024 earnings released: EPS: ₹1.39 (vs ₹0.24 loss in 2Q 2023)Second quarter 2024 results: EPS: ₹1.39 (up from ₹0.24 loss in 2Q 2023). Revenue: ₹1.67b (up 5.0% from 2Q 2023). Net income: ₹117.3m (up ₹137.3m from 2Q 2023). Profit margin: 7.0% (up from net loss in 2Q 2023). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 54% per year but the company’s share price has increased by 12% per year, which means it is well ahead of earnings.
お知らせ • Nov 03SMS Pharmaceuticals Limited to Report Q2, 2024 Results on Nov 08, 2023SMS Pharmaceuticals Limited announced that they will report Q2, 2024 results on Nov 08, 2023
分析記事 • Sep 24SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) CEO Compensation Is Looking A Bit Stretched At The MomentKey Insights SMS Pharmaceuticals will host its Annual General Meeting on 30th of September Total pay for CEO Ramesh...
Upcoming Dividend • Sep 15Upcoming dividend of ₹0.30 per share at 0.2% yieldEligible shareholders must have bought the stock before 22 September 2023. Payment date: 29 October 2023. The company is not currently making a profit and is not cash flow positive. Trailing yield: 0.2%. Lower than top quartile of Indian dividend payers (1.3%). Lower than average of industry peers (0.9%).
分析記事 • Sep 11SMS Pharmaceuticals' (NSE:SMSPHARMA) Dividend Will Be ₹0.30The board of SMS Pharmaceuticals Limited ( NSE:SMSPHARMA ) has announced that it will pay a dividend of ₹0.30 per share...
分析記事 • Aug 28SMS Pharmaceuticals (NSE:SMSPHARMA) Has Announced A Dividend Of ₹0.30SMS Pharmaceuticals Limited ( NSE:SMSPHARMA ) will pay a dividend of ₹0.30 on the 29th of October. This payment means...
お知らせ • Aug 09SMS Pharmaceuticals Limited, Annual General Meeting, Sep 30, 2023SMS Pharmaceuticals Limited, Annual General Meeting, Sep 30, 2023.
Reported Earnings • Aug 09First quarter 2024 earnings released: EPS: ₹1.10 (vs ₹1.51 loss in 1Q 2023)First quarter 2024 results: EPS: ₹1.10 (up from ₹1.51 loss in 1Q 2023). Revenue: ₹1.36b (up 111% from 1Q 2023). Net income: ₹93.4m (up ₹221.1m from 1Q 2023). Profit margin: 6.9% (up from net loss in 1Q 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 43% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings.
お知らせ • Aug 03SMS Pharmaceuticals Limited to Report Q1, 2024 Results on Aug 08, 2023SMS Pharmaceuticals Limited announced that they will report Q1, 2024 results on Aug 08, 2023
Board Change • Jul 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 3 highly experienced directors. Executive Director Vamsi Potluri was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
分析記事 • Jun 07SMS Pharmaceuticals (NSE:SMSPHARMA) Has A Somewhat Strained Balance SheetDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Reported Earnings • May 26Full year 2023 earnings released: ₹0.83 loss per share (vs ₹7.35 profit in FY 2022)Full year 2023 results: ₹0.83 loss per share (down from ₹7.35 profit in FY 2022). Revenue: ₹5.27b (up 1.4% from FY 2022). Net loss: ₹70.6m (down 111% from profit in FY 2022). Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has increased by 28% per year, which means it is well ahead of earnings.
お知らせ • May 25SMS Pharmaceuticals Limited Recommends Dividend for the Financial Year 2022-2023The board of directors of SMS Pharmaceuticals Limited at its AGM held on May 24, 2023, recommended the Dividend of INR 0.30 (30%) per equity share of face value of INR 1.00 each for the financial year 2022-23, subject To Approve the members at the upcoming annual general meeting. The AGM date and book closure/record date for the purpose of the payment of dividend will be informed in due course.
お知らせ • May 19SMS Pharmaceuticals Limited to Report Q4, 2023 Results on May 24, 2023SMS Pharmaceuticals Limited announced that they will report Q4, 2023 results at 12:08 PM, Indian Standard Time on May 24, 2023
Reported Earnings • Feb 10Third quarter 2023 earnings released: EPS: ₹0.44 (vs ₹1.07 in 3Q 2022)Third quarter 2023 results: EPS: ₹0.44 (down from ₹1.07 in 3Q 2022). Revenue: ₹1.51b (up 22% from 3Q 2022). Net income: ₹37.6m (down 58% from 3Q 2022). Profit margin: 2.5% (down from 7.3% in 3Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has increased by 22% per year, which means it is well ahead of earnings.
お知らせ • Feb 01SMS Pharmaceuticals Limited to Report Q3, 2023 Results on Feb 09, 2023SMS Pharmaceuticals Limited announced that they will report Q3, 2023 results on Feb 09, 2023
Reported Earnings • Nov 16Second quarter 2023 earnings released: ₹0.24 loss per share (vs ₹2.72 profit in 2Q 2022)Second quarter 2023 results: ₹0.24 loss per share (down from ₹2.72 profit in 2Q 2022). Revenue: ₹1.60b (down 9.1% from 2Q 2022). Net loss: ₹20.1m (down 109% from profit in 2Q 2022). Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has increased by 30% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • Nov 11Investor sentiment improved over the past weekAfter last week's 18% share price gain to ₹105, the stock trades at a trailing P/E ratio of 34.5x. Average trailing P/E is 25x in the Pharmaceuticals industry in India. Total returns to shareholders of 165% over the past three years.
分析記事 • Sep 23Shareholders May Not Be So Generous With SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) CEO Compensation And Here's WhySMS Pharmaceuticals Limited ( NSE:SMSPHARMA ) has exhibited strong share price growth in the past few years. However...
Upcoming Dividend • Sep 15Upcoming dividend of ₹0.30 per shareEligible shareholders must have bought the stock before 22 September 2022. Payment date: 30 October 2022. Payout ratio is a comfortable 9.8% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of Indian dividend payers (1.5%). Lower than average of industry peers (1.0%).
分析記事 • Sep 15SMS Pharmaceuticals (NSE:SMSPHARMA) Is Due To Pay A Dividend Of ₹0.30The board of SMS Pharmaceuticals Limited ( NSE:SMSPHARMA ) has announced that it will pay a dividend on the 30th of...
分析記事 • Sep 01SMS Pharmaceuticals (NSE:SMSPHARMA) Will Pay A Dividend Of ₹0.30SMS Pharmaceuticals Limited ( NSE:SMSPHARMA ) has announced that it will pay a dividend of ₹0.30 per share on the 30th...
Reported Earnings • Aug 18First quarter 2023 earnings released: ₹1.51 loss per share (vs ₹2.78 profit in 1Q 2022)First quarter 2023 results: ₹1.51 loss per share (down from ₹2.78 profit in 1Q 2022). Revenue: ₹651.9m (down 60% from 1Q 2022). Net loss: ₹127.7m (down 154% from profit in 1Q 2022). Over the last 3 years on average, earnings per share has increased by 21% per year whereas the company’s share price has increased by 23% per year.
分析記事 • Aug 18SMS Pharmaceuticals (NSE:SMSPHARMA) Has Announced A Dividend Of ₹0.30The board of SMS Pharmaceuticals Limited ( NSE:SMSPHARMA ) has announced that it will pay a dividend on the 30th of...
Reported Earnings • Jun 02Full year 2022 earnings released: EPS: ₹7.35 (vs ₹7.39 in FY 2021)Full year 2022 results: EPS: ₹7.35 (down from ₹7.39 in FY 2021). Revenue: ₹5.25b (down 7.1% from FY 2021). Net income: ₹622.2m (flat on FY 2021). Profit margin: 12% (in line with FY 2021). Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Mar 22Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₹112, the stock trades at a trailing P/E ratio of 12x. Average trailing P/E is 25x in the Pharmaceuticals industry in India. Total returns to shareholders of 78% over the past three years.
分析記事 • Mar 22We Think SMS Pharmaceuticals (NSE:SMSPHARMA) Can Stay On Top Of Its DebtThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Reported Earnings • Feb 10Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: EPS: ₹1.07 (down from ₹2.53 in 3Q 2021). Revenue: ₹1.23b (down 18% from 3Q 2021). Net income: ₹89.6m (down 58% from 3Q 2021). Profit margin: 7.3% (down from 14% in 3Q 2021). The decrease in margin was driven by lower revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has only increased by 20% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Nov 15Second quarter 2022 earnings released: EPS ₹2.72 (vs ₹1.30 in 2Q 2021)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2022 results: Revenue: ₹1.76b (up 34% from 2Q 2021). Net income: ₹230.3m (up 110% from 2Q 2021). Profit margin: 13% (up from 8.4% in 2Q 2021). The increase in margin was driven by higher revenue.
Upcoming Dividend • Sep 15Upcoming dividend of ₹0.30 per shareEligible shareholders must have bought the stock before 22 September 2021. Payment date: 30 October 2021. Trailing yield: 0.2%. Lower than top quartile of Indian dividend payers (1.5%). Lower than average of industry peers (0.7%).
Reported Earnings • Aug 09First quarter 2022 earnings released: EPS ₹2.78 (vs ₹0.83 in 1Q 2021)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2022 results: Revenue: ₹1.64b (up 45% from 1Q 2021). Net income: ₹235.6m (up 235% from 1Q 2021). Profit margin: 14% (up from 6.2% in 1Q 2021). The increase in margin was driven by higher revenue.
Valuation Update With 7 Day Price Move • Jun 14Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹184, the stock trades at a trailing P/E ratio of 24.6x. Average trailing P/E is 24x in the Pharmaceuticals industry in India. Total returns to shareholders of 143% over the past three years.
